CNC price target cut on recent selloff

What happened: On March 19, JPMorgan cut its price target on Centene Corporation (CNC) to $41 from $45, maintaining a Neutral rating, following the stock's 16% selloff in the past week. Meanwhile, TCW Relative Value Mid Cap Fund, managed by TCW funds, listed CNC as one of its holdings in the fourth quarter of 2022. Notably, hedge fund manager David Einhorn's Greenlight Capital has been increasing its stake in CNC since the first quarter of 2020.

Market impact: The price target cut by JPMorgan, coupled with the recent selloff, has negatively impacted CNC's valuation, affecting investors with exposure to the managed care sector. The selloff may also be influencing other stocks in the healthcare sector, as seen in the 38% upside of Centessa Pharmaceuticals (CNTA) following its acquisition announcement, pushing CNTA to an all-time high.

What to watch next: Investors should closely monitor CNC's earnings release scheduled for April 27, 2023, to gauge the company's financial health and potential recovery. Additionally, any updates on the Eli Lilly and Company's acquisition of Centessa Pharmaceuticals, expected to close in the second half of 2023, could further impact the healthcare sector. Lastly, technical traders may watch CNC's support levels around $41, as a break below this level could signal further downside.